CartiHeal

Cell-free Cartilage Regeneration

Health Tech & Life Sciences
Acquired by Smith & Nephew on Nov 2023

Company Overview

Snapshot

Founded in June 2009 by Nir Altschuler, CartiHeal operated with 11–50 employees. The company raised a total of $74 million across 7 funding rounds from 8 investors. In November 2023, CartiHeal was acquired by Smith & Nephew.

Business overview

CartiHeal develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. Its core product, Agili-C, is a cell-free, off-the-shelf, rigid, biphasic, and biodegradable implant designed to enhance bone formation and regenerate cartilage. The company serves the medical device market, focusing on orthopedics and regenerative medicine within the Health Tech & Life Sciences sector.

Strategic signal

In November 2023, CartiHeal was acquired by Smith & Nephew for up to $330 million, marking a significant exit for the company and its investors. This acquisition validates CartiHeal's innovative Agili-C implant technology and its potential to address cartilage and osteochondral defects, signaling strong commercial interest in advanced regenerative medicine solutions within the orthopedic market.

Company Intelligence Q&A

What was the most recent significant corporate event for CartiHeal?
In November 2023, CartiHeal was acquired by Smith & Nephew for up to $330 million.
When did CartiHeal receive FDA Breakthrough Device Designation for its Agili-C implant?
In October 2020, CartiHeal's Agili-C implant was granted Breakthrough Device Designation by the US FDA.
When was the Agili-C implant first commercially implanted in the US?
In July 2023, CartiHeal announced the first commercial implantation of its Agili-C implant in the US.
Which investors participated in CartiHeal's May 2017 funding round?
CartiHeal received funding in May 2017 from investors including Peregrine Ventures and Johnson & Johnson Innovation.
When did the FDA approve CartiHeal's implant for cartilage and osteochondral defects?
The FDA approved CartiHeal's implant for the treatment of cartilage and osteochondral defects in March 2022.

External links